Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neighbourly Pharmacy Inc T.NBLY

Neighbourly Pharmacy Inc. is a Canada-based company that operates a network of community pharmacies. The Company is an owner and operator of retail pharmacies located throughout Canada under banners such as IDA/Guardian, Pharmachoice, Pharmasave and Remedy’s RX. The Company, through its subsidiaries, owns and operates a network of retail pharmacies known as Rubicon Pharmacies (Rubicon or Rubicon Pharmacies. The Company owns and operates approximately 287 locations across seven provinces and one territory, a coast-to-coast footprint that provides scale and diversification. The Company’s pharmacies provide accessible healthcare with a personal touch. The Company also owns British Columbia-based pharmacies.


TSX:NBLY - Post by User

Post by retiredcfon Aug 07, 2023 9:53am
109 Views
Post# 35576041

Another View

Another View

EPS of $0.11 beat estimates of $0.06; revenue of $196.8M marginally beat estimates. Same store growth was decent at 4.1% and EBITDA rose 77%. Sales rose 72%, with most of this (95%) from acquisitions. But execution improved and the company notes better topline momentum. Store count rose from 175 to 291. SG&A costs fell to 3.5% from 4% of sales. The company has only beaten estimates three times in the past eight quarters, but this was a good result for NBLY and (maybe) the stock can start to form a bottom here. (5iResearch)

 

<< Previous
Bullboard Posts
Next >>